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Abstract In L6E9 skeletal muscle cells ternary complex factor
(TCF) Elk-1 expression increased with the onset of skeletal
muscle di¡erentiation, whereas its activation decreased as a
function of di¡erentiation. Its expression was predominantly
restricted to cytoplasm and activated ones were predominantly
restricted to the nucleus of the di¡erentiated cells. Inhibition of
ERK-1/-2 activities by PD098059 resulted into signi¢cant re-
duction in Elk-1 expression and phosphorylation during di¡er-
entiation. In contrast, inhibition of p38 mitogen-activated pro-
tein kinase (MAPK) enhanced Elk-1 expression and activation,
thereby mediating inhibition of skeletal muscle di¡erentiation.
Overexpression of inactive mutant Elk-1 enhanced di¡erentia-
tion. Data suggest that ERK-1/-2 and p38 MAPK activities
modulate Elk-1 expression and activation to regulate skeletal
muscle di¡erentiation. 5 2002 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
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1. Introduction
Mitogen-activated protein kinases (MAPK) are involved in
various cellular processes such as cell growth, di¡erentiation
and apoptosis [1]. Much emphasis has been made on MAPK’s
involvement in various cellular processes however little is
understood with regard to the role of transcription factors
activated by them. Previously, we have reported that inhibi-
tion of ERK-1/-2 activity dramatically enhanced skeletal
muscle di¡erentiation; in contrast, inhibition of p38 MAP
kinase completely prevented di¡erentiation [2]. Moreover,
ERK-1/-2 and p38 MAPK regulated each other’s activities
[2]. Recent evidence suggests that ternary complex factor
(TCF) Elk-1 is a target of all three classes of MAP kinases
ERK, JNK, and p38 MAPK [3]. Multiple MAP kinase sites
are located in the C-terminal domains of Elk-1, which are
phosphorylated by ERK, JNK, and p38 MAP kinases in vitro
and in vivo [4]. This indicates that multiple MAP kinase path-
ways can converge on the TCFs. Elk-1 functions as a nuclear
transcriptional activator via its association with serum re-
sponse factor (SRF) and serum response element (SRE)
present on the promoter of many immediate early genes
such as c-fos, egr1, egr2, pip 92, and nurr77 [5]. The phos-
phorylation of TCFs, Elk and SAP-1 leads to enhanced DNA
binding and TCF-mediated transcriptional activation [4]. No
data yet indicate the role of Elk-1 in skeletal muscle di¡er-
entiation in vivo.
In the present report we have extended our previous study
in determining the activation pro¢le of Elk-1 to understand
the physiological signi¢cance in L6E9 skeletal muscle di¡er-
entiation. Our data suggest a possible correlation between
MAPK activity and activation of Elk-1 in regulating L6E9
skeletal muscle di¡erentiation.
2. Materials and methods
2.1. Materials
Rat skeletal muscle cell line L6E9 was kindly provided by Dr. H.
Blau, Stanford University School of Medicine, Stanford, USA and
Dr. J. Dhawan, CCMB, India. PD098059 and SB203580 were pur-
chased from Calbiochem, USA. Anti-phospho-Elk-1 antibody and
anti-actin antibody were procured from Santa Cruz Biotechnology,
USA. Anti-Elk-1 antibody was procured from Cell Signalling Tech-
nology, USA. Horse serum, Dulbecco’s modi¢ed Eagle’s medium
(DMEM) were purchased from Gibco BRL, USA. Fetal calf serum
(FCS) was purchased from Biological Industries, Israel. Other re-
agents were obtained from Sigma, USA and Bio-Rad, USA. Trans-
Fast transfection reagent was obtained from Promega Corporation,
USA. The pCMVElk-1 (S383/S389) expression plasmid was a gener-
ous gift from Dr. Ralf Janknecht of Mayo Clinic, Rochester, USA.
2.2. Cell culture
L6E9 rat skeletal muscle cells were proliferated in DMEM supple-
mented with 15% FCS and antibiotics for 2 days. Di¡erentiation was
initiated by shifting 70% con£uent cells to DMEM supplemented with
2% horse serum for 4 days (fully di¡erentiated) at 37‡C in 5% CO2
incubator. Di¡erentiation medium was changed daily.
2.3. Cell lysis
Cells were washed in ice-cold phosphate-bu¡ered saline (PBS) and
lysed in lysis bu¡er containing 20 mM Tris (pH 7.5), 150 mM NaCl,
1 mM ethylenediamine tetraacetic acid (EDTA), 1 mM ethylenegly-
col-bis-(L-aminoethylether)-N,N,NP,NP-tetraacetic acid (EGTA), 1%
Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM L-glycerophos-
phate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl
£uoride (PMSF) and 10 Wg/ml each of leupeptin and aprotinin at 4‡C
for 20 min. The lysates were centrifuged at 16 000Ug at 4‡C for
10 min. The supernatants were collected and samples were frozen at
320‡C until used.
2.4. Western immunoblotting
Proteins were resolved in sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE) and transferred to nitrocellulose
membrane (NC) and blocked for 1 h at room temperature in 5%
bovine serum albumin (BSA) in TBST (10 mM Tris^HCl, pH 8.0,
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150 mM NaCl, 0.05% Tween-20). The NC membrane was washed and
incubated with primary antibodies (anti-Elk-1, anti-phospho-Elk-1
and anti-actin antibody) for overnight at 4‡C. Proteins were detected
by alkaline phosphatase-conjugated secondary antibody using 5-bro-
mo-4-chloro-3-indolyl-phosphate/nitroblue tetrazolium (BCIP/NBT)
as a substrate or by chemiluminescence. Blots were stripped in strip-
ping bu¡er (62.5 mM Tris^HCl, pH 6.7, 2% SDS and 100 mM
L-mercaptoethanol) at 50‡C for 30 min and reprobed with anti-phos-
pho-Elk-1 antibody.
2.5. Creatine kinase (CK) assay
The assay was performed according to standard protocol [6]. The
change in absorbance was measured at 340 nm up to 5 min.
2.6. Cellular fractionation
Cells were fractionated according to Vandromme et al. [7]. Brie£y,
cells were lysed in hypotonic bu¡er containing 10 mM Tris^HCl (pH
7.4), 10 mM NaCl, 1 mM EDTA, 1 mM PMSF, 4 WM leupeptin and
aprotinin (2 Wg/ml) and homogenized. Nuclei were collected by 10 min
centrifugation at 2000Ug and supernatant was taken as cytosol. Pellet
was ¢nally suspended in equal amount of Laemmli’s sample bu¡er [8].
2.7. Treatment of cells by inhibitors
PD098059 and SB203580 were dissolved in dimethyl sulfoxide
(DMSO) separately to the concentration of 10 mM each and were
added directly to di¡erentiation medium to a ¢nal concentration of 10
WM. Control was incubated with the same volumes of DMSO without
inhibitors. The medium was replaced every 24 h with medium con-
taining fresh inhibitors. At this concentration of the inhibitors there
was no toxic e¡ect observed as cells di¡erentiated normally when the
drug was withdrawn from the medium (data not shown).
2.8. Transient transfection
Exponentially growing L6E9 cells were transfected with 5 Wg of
Elk-1 (S383/S389) expression plasmid using TransFast transfection
reagent according to manufacturer’s instructions. 36 h after transfec-
tion cells were transferred in di¡erentiation medium for 4 days. De-
gree of di¡erentiation was determined by creatine kinase activity and
overexpression was measured by Western immunoblot using anti-
Elk-1 antibody.
2.9. Protein estimation
The protein concentration was estimated by Lowry’s method [9]
using BSA as a standard protein.
2.10. Densitometric analysis
Densitometric analysis of the Western immunoblots was performed
by using a GS-670 Imaging Densitometer (Bio-Rad) and Molecular
Analyst software (version 1.3, Bio-Rad). Control samples in each ex-
periment were given an arbitrary value of 1.0 for calculating the rel-
ative value of the other samples.
3. Results
3.1. Increase in expression of Elk-1 during di¡erentiation of
L6E9 skeletal muscle cells
We determined the expression of Elk-1 as a function of
L6E9 skeletal muscle di¡erentiation by Western immunoblot-
ting probed with anti-Elk-1 antibody. Fig. 1A, upper panel,
shows that expression of Elk-1 was low in proliferating myo-
blasts, whereas it was signi¢cantly (350%) higher in di¡eren-
tiated myotubes as compared to proliferating cells (Fig. 1A,
lower panel, lane 1 vs. lane 5). This increase of Elk-1 was
speci¢c because under the similar conditions levels of actin
remained unchanged (Fig. 1B). Increase in Elk-1 expression
with the onset of skeletal muscle di¡erentiation suggests in-
volvement of Elk-1 as a function of di¡erentiation.
3.2. Decrease of phosphorylation of Elk-1 during di¡erentiation
of L6E9 skeletal muscle cells
We next evaluated the phosphorylation of Elk-1, which is
an indication of activation of the transcription factor, as a
function of di¡erentiation. Immunoblot of Elk-1 shown in
Fig. 1A was stripped and reprobed with anti-phospho-Elk-1
antibody (Fig. 1C). Elk-1 was highly phosphorylated in pro-
liferating myoblasts (Fig. 1C, upper panel, lane 1) whereas
Elk-1 phosphorylation was decreased during di¡erentiation
(130% decrease in fully di¡erentiated cells as compared to
proliferated cells ; Fig. 1C, lanes 2^5). Data indicate that acti-
Fig. 1. Increase in Elk-1 expression during di¡erentiation of L6E9
skeletal muscle cells. Cells were lysed at indicated intervals of time
and were resolved on SDS^PAGE followed by Western immuno-
blotting with anti-Elk-1 antibody (A) or with anti-actin antibody
(B). Elk-1 immunoblot was stripped and reprobed with anti-phos-
pho-Elk-1 antibody (C) as mentioned in Section 2. P, proliferated
cells. Upper panel: Western blot; lower panel: respective graphical
representations. The experiments were carried out four times with
similar results. One representative blot has been presented. The re-
sults are presented as meanQS.E.M. for four independent experi-
ments.
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vation of Elk-1 decreases with the di¡erentiation. This sug-
gests that decrease in Elk-1 phosphorylation is associated with
skeletal muscle di¡erentiation.
3.3. Inhibition of ERK-1/-2 activities by PD098059 causes
decrease in Elk-1 expression and phosphorylation during
L6E9 skeletal muscle di¡erentiation
In our previous report [2] we have demonstrated inhibition
of ERK-1/-2 and stimulation of p38 MAP kinase activity
during the di¡erentiation of L6E9 rat skeletal muscle cells.
Complete inhibition of ERK-1/-2 activity by PD098059 dra-
matically enhanced di¡erentiation, suggesting that ERK-1/-2
activation may be inhibitory to initiation and progression of
di¡erentiation [2]. In contrast, inhibition of p38 MAP kinase
by SB203590 completely prevented di¡erentiation; meaning
p38 activation is required from the initiation till terminal dif-
ferentiation of L6E9 cells [2]. To evaluate the interaction be-
tween ERK-1/-2 and Elk-1 as a function of di¡erentiation, if
any, we determined the expression and activation of Elk-1
under the condition where ERK-1/-2 activities were inhibited
by PD098059. Fig. 2A, lanes 6^9, shows that expression of
Elk-1 was decreased (60% decrease in fully di¡erentiated cells,
lane 9) when the cells were di¡erentiated in presence of
PD098059. Data suggest ERK-1/-2 activities regulate expres-
sion of transcription factor Elk-1. We next investigated Elk-1
phosphorylation in fully di¡erentiated myotubes in absence or
presence of PD098059. Fig. 2B indicates that phosphorylation
of Elk-1, which was decreased in di¡erentiated myotubes, was
further decreased (80%) in presence of PD098059. Data sug-
gest ERK-1/-2 activities regulate expression and activation of
transcription factor Elk-1. In order to ¢nd out the involve-
ment of Elk-1 in regulating di¡erentiation, e¡ect of PD098059
on creatine kinase activity was measured and the activity was
signi¢cantly increased (28%) in myotubes di¡erentiated in
presence of PD098059 (Fig. 2C, lane PD) as compared to
di¡erentiated cells (Fig. 2C, lane D). Data suggest that
ERK and Elk-1 activities negatively regulate skeletal muscle
di¡erentiation.
3.4. Increase in expression of Elk-1 is predominant in
cytoplasm and not in nucleus during L6E9 skeletal
muscle di¡erentiation
Elk-1 is classically described as a nuclear target of activated
ERK [10]; however, a recent report suggests that activated
Elk-1 is present in both cytoplasm and nucleus of post mitotic
neurons [11]. Therefore, to test this possibility we next inves-
tigated whether increase in Elk-1 expression during skeletal
muscle di¡erentiation was limited to cytoplasm or nucleus.
Fig. 3A shows that Elk-1 expression was predominantly
6
Fig. 2. Decreased Elk-1 expression and activation on treatment with
PD098059 during di¡erentiation of L6E9 skeletal muscle cells. Cells
were di¡erentiated in absence or presence of PD09859 and were
lysed at indicated intervals of time. Samples were resolved on SDS^
PAGE followed by Western immunoblotting with (A) anti-Elk-1
antibody, (B) anti-phospho-Elk-1 antibody. C: Creatine kinase ac-
tivity was assayed as indicated in Section 2. P, proliferated cells; D,
di¡erentiated cells ; PD, cells di¡erentiated in presence of 10 WM
PD098059. Upper panels: Western blots: lower panels: respective
graphical representations. The experiments were carried out three
times with similar results. One representative blot has been pre-
sented. The results are presented as meanQS.E.M. for three inde-
pendent experiments (*P6 0.01).
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present in cytoplasm and not in nucleus, in di¡erentiated
L6E9 skeletal muscle cells (lane 3 vs. lane 4). However,
when the cells were di¡erentiated in presence of PD098059,
Elk-1 expression was abrogated in both cytoplasm and nu-
cleus (Fig. 3A, lanes 5 and 6). Data indicate that although
Elk-1 expression was increased with the skeletal muscle di¡er-
entiation, its expression was limited to cytoplasm and not in
nucleus in di¡erentiating L6E9 cells (Fig. 3A). Elk-1 present
in cytoplasm was not activated whereas Elk-1 present inside
the nucleus was (Fig. 3B).
3.5. Inhibition of p38 MAPK by SB203580 increases
expression and activation of Elk-1 during L6E9 skeletal
muscle di¡erentiation
Since Elk-1 is thought to be a convergence point for all
MAPK pathways [3,12], we determined the e¡ect of p38
MAPK on Elk-1. Previously we have shown that inhibition
of p38 MAPK by SB203580 inhibited skeletal muscle di¡er-
entiation and activated ERK-1/-2 activities during di¡erentia-
tion [2]. Therefore, we determined Elk-1 expression and phos-
phorylation in the cells di¡erentiated in absence and presence
of SB203580. Fig. 4A shows that when the cells were di¡er-
entiated in presence of SB203580, Elk-1 expression was sig-
ni¢cantly (22%) increased as a function of di¡erentiation (Fig.
4A, lanes 6^9). Cellular fractionation studies showed that in-
creased Elk-1 expression on treatment of SB203580 was lim-
ited to cytoplasm and not in the nucleus (Fig. 3A, lanes 7 and
8). Therefore, data suggest that induction of Elk-1 expression
by inhibition of p38 MAPK might be involved in inhibition of
skeletal muscle di¡erentiation. We next investigated the e¡ect
of SB203580 treatment on activation of Elk-1 as a function of
di¡erentiation of L6E9 cells. Fig. 4B indicates that on inhibi-
tion of p38 MAPK, the Elk-1 was activated, however, under
the same condition, creatine kinase activity was decreased
(31%) (Fig. 4C, compare lane D and lane SB) as compared
to di¡erentiated cells. Data suggest that p38 MAPK-mediated
Elk-1 regulation controls skeletal muscle di¡erentiation.
3.6. Inactive Elk-1 (S383/S389) mutant induces skeletal muscle
di¡erentiation
It has been shown that phosphorylation of serines 383 and
389 of Elk-1 is critical for the transcriptional activation of
Elk-1 [13]. Ser-383 and Ser-389 have previously been shown
to be major ERK2 phosphorylated residues [14]. These two
residues are major determinants of ERK-2 stimulated DNA
binding and transcriptional activation by Elk-1 [14]. Mutation
of either the phosphoacceptor sites (S383/S389) caused reduc-
tion in rate and extent of phosphorylation of each of these
mutants [15]. We transiently transfected Elk-1 S383/S389 to
evaluate the e¡ect of inactive Elk-1 mutant on skeletal muscle
di¡erentiation. Transfected cells showed overexpression of in-
active mutant Elk-1 protein (Fig. 5A) as compared to cells
transfected with empty vector when checked by Western
blot analysis by probing with anti-Elk-1 antibody. Transfected
cells were di¡erentiated and signi¢cant increase in di¡erentia-
tion was observed as determined by creatine kinase activity
(35%) (Fig. 5B). Results suggest that overexpression of inac-
tive Elk-1 enhances di¡erentiation in L6E9 skeletal muscle
cells.
4. Discussion
In our previous report we have shown that when the cells
were di¡erentiated in presence of PD098059, extensive myo-
tube formation and increased creatine kinase activity were
observed [2]. Under this condition Elk-1 activation was com-
pletely inhibited and expression was signi¢cantly decreased as
shown in the present study (Fig. 2A and B). This indicates
that ERK-1/-2 activities regulate expression as well as phos-
Fig. 3. Elk-1 is predominantly present in cytoplasm and not in nu-
cleus of di¡erentiated L6E9 cells. A: Cells were lysed and cytoplas-
mic (C) and nuclear (N) fractions were prepared as described in Sec-
tion 2. Samples were resolved on SDS^PAGE followed by Western
immunoblotting with anti-Elk-1 antibody. Lanes 1, 3, 5, and 7 rep-
resent cytoplasmic fractions of proliferated cells (P), di¡erentiated
cells (D), cells di¡erentiated in presence of PD098059 (PD), cells dif-
ferentiated in presence of SB203580 (SB). Lanes 2, 4, 6, and 8 rep-
resent nuclear fraction of above treated samples respectively.
B: Above mentioned samples were resolved in SDS^PAGE followed
by Western immunoblotting with anti-phospho-Elk-1 antibody.
Graphical representation of only nuclear fractions is given in lower
panel. Upper panels: Western blots; lower panels: respective graphi-
cal representations. The experiments were carried out three times
with similar results. One representative blot has been presented. The
results are presented as meanQS.E.M. for three independent experi-
ments (*P6 0.001).
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phorylation of Elk-1. Decrease in Elk-1 expression and phos-
phorylation, increase in CK activity, as observed in our cur-
rent study, may be responsible for hyperdi¡erentiation ob-
served due to PD098059 treatment as observed in our
previous report [2]. In contrast, when the cells were di¡eren-
tiated in presence of SB203580, skeletal muscle di¡erentiation
was inhibited completely [2] and Elk-1 expression and phos-
phorylation were signi¢cantly increased (Fig. 4A and B). This
suggests that inhibition of skeletal muscle di¡erentiation due
to p38 MAPK inhibition was mediated by increasing the ex-
pression as well as phosphorylation of Elk-1.
The increase in expression and decrease in phosphorylation
of Elk-1 under low ERK activity during skeletal muscle di¡er-
entiation were a paradox. Data observed from our cellular
fractionation studies (Fig. 3A, lane 3 vs. lane 4) may be ex-
plained as ERK-1/-2 activities decrease with skeletal muscle
Fig. 5. Inactive Elk-1 (S383/S389) mutant induces skeletal muscle
di¡erentiation. Proliferating L6E9 cells were transfected with mu-
tated Elk-1 (S383/S389) expression vector (pCMVElk-1 S383/S389)
or empty vector (pCMV). A: Transfected proliferated cells were
lysed and were resolved on SDS^PAGE followed by Western immu-
noblotting with anti-Elk-1 antibody. B: The transfected cells were
incubated for 4 days in di¡erentiation medium and ¢nally processed
for creatine kinase activity as mentioned in Section 2. Vector:
pCMV-transfected cells ; Elk-1 S383/S389: pCMVElk-1 S383/S389-
transfected cells. The results are presented as meanQS.E.M. for
three independent experiments (*P6 0.01).
6
Fig. 4. Increased Elk-1 expression and activation on treatment with
SB203580 during di¡erentiation of L6E9 skeletal muscle cells.
A: Cells were di¡erentiated in absence or presence of SB203580 and
were lysed at indicated intervals of time. Samples were resolved on
SDS^PAGE followed by Western immunoblotting with anti-Elk-1
antibody. B: Fully di¡erentiated cells in presence or absence of
SB203580 were lysed and resolved on SDS^PAGE and processed
for immunoblotting with anti-phospho-Elk-1 antibody as mentioned
in Section 2. C: Creatine kinase activity was assayed as indicated in
Section 2. P, proliferated cells; D, di¡erentiated cells ; SB, cells dif-
ferentiated in presence of 10 WM SB203580. Upper panels: respec-
tive Western blots; lower panels: respective graphical representa-
tions. The experiments were carried out three times with similar
results. One representative blot has been presented. The results are
presented as meanQS.E.M. for three independent experiments
(*P6 0.01).
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di¡erentiation [2], thereby less Elk-1 is activated (Fig. 1B),
hence little translocation of Elk-1 into the nucleus takes place
(Fig. 3A, lane 4). However, in proliferating cell expression of
Elk-1 was very less (Fig. 1, lane 1) when compared to di¡er-
entiated skeletal muscle cells (Fig. 1, lane 5), but Elk-1 was
highly phosphorylated; therefore, most of the Elk-1 was
present in the nucleus of the proliferating cells (Fig. 3B,
lane 2). Transfection studies with inactive Elk-1 S383/S389
mutant revealed that overexpression of inactive Elk-1 en-
hanced skeletal muscle di¡erentiation (Fig. 5B). This ¢nding
in conjunction with others, as mentioned above, strongly sug-
gest that inactivation of Elk-1 is required for skeletal muscle
di¡erentiation. Recently, Elk-1 phosphorylation has been de-
scribed to play an important role in nerve growth factor-in-
duced PC12 neuronal di¡erentiation [16]. Previously, acti-
vated Elk-1 was reported to be present in both the
cytoplasmic and nuclear compartments of the neuronal cell
types [11]. Our study on L6E9 skeletal muscle cells reveals
presence of activated Elk-1 in the nucleus only. Recent reports
suggest a link between Elk-1 activation and neuronal di¡er-
entiation [11,16,17]. The involvement of Elk-1 phosphoryla-
tion has also been implicated in breast cancer cells [18]. How-
ever, to the best of our knowledge we are reporting for the
¢rst time the involvement of Elk-1 in skeletal muscle di¡er-
entiation. In conclusion, our data suggest that MAPK con-
verge at Elk-1 and modulation of Elk-1 expression and acti-
vation by MAPK may regulate skeletal muscle di¡erentiation.
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